Search clinical trials for: UMEC

Total 59 results

GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Romania, Russian Federation, Ukraine, Germany, Hungary, Bulgaria
GlaxoSmithKline
Optum-data vendor

Completed

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline
Parexel

Completed

A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline
Parexel

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Asthma

United States
GlaxoSmithKline

Completed

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Pulmonary Disease, Chronic Obstructive

United States
Medigreen Biotechnology Corp.

Unknown

Safety Study of Anti-Asthma Agent BMEC-1217B

Asthma

Taiwan
Weill Medical College of Cornell University
Angiocrine Bioscience

Recruiting

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Anal Fistula

United States
University of Sao Paulo General Hospital
University of Nebraska

Recruiting

Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease (HUBBLE-I)

Acute Myocardial Infarction | Unstable Angina

United States, Brazil
GlaxoSmithKline

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

India
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Chile, Romania, Canada
GlaxoSmithKline

Completed

Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Germany, Poland, Romania, Russian Federation, Ukraine
GlaxoSmithKline

Completed

A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

Pulmonary Disease, Chronic Obstructive

Germany, United States, Korea, Republic of, Czech Republic
GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline

Completed

To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD

Pulmonary Disease, Chronic Obstructive

China
University of Manitoba

Completed

Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis (PCA)

Psoriasis

Canada
Dr. Grace Parraga
GlaxoSmithKline

Active, not recruiting

Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (ETHA)

Asthma

Canada
University of Sao Paulo General Hospital
University of Nebraska

Completed

Therapeutic Use of Ultrasound in Acute Coronary Artery Disease

Acute Myocardial Infarction

Brazil
Banc de Sang i Teixits

Completed

Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 (COVIDMES)

COVID-19 | SARS-CoV 2 | Adult Respiratory Distress Syndrome

Spain
Swiss Group for Clinical Cancer Research

Completed

VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Bladder Cancer

Switzerland, Germany
GlaxoSmithKline

Completed

INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design

Pulmonary Disease, Chronic Obstructive

Germany, Spain, Netherlands, Sweden, United Kingdom
GlaxoSmithKline

Completed

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, Japan, Russian Federation, Spain, Germany, Mexico, Romania, Korea, Republic of, Poland, Italy, France
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
Fred Hutchinson Cancer Center
National Institute on Aging (NIA)

Completed

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance (MsFLASH-04)

Hot Flashes | Sleep | Menopause | Vasomotor Disturbance

United States
Banc de Sang i Teixits
Syntax for Science, S.L; Hospital de Neurorehabilitació Institut Guttmann; Recerca...

Completed

Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury

Spinal Cord Injury, Chronic

Spain
Research Institute for Complex Problems of Cardiovascular...

Completed

Myeloid-Derived Supressor Cells in Cardiac Surgery Patients (MyDeCCS)

Systemic Inflammatory Response Syndrome | Insufficiency; Cardiac, Complicating Surgery

Russian Federation
Zhongshan Ophthalmic Center, Sun Yat-sen University

Recruiting

Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD

Dry Eye

China
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
GlaxoSmithKline

Completed

CV Events in Emetogenic Chemotherapy

Vomiting | Cardiovascular Event | Arterial Thromboembolic Event
Hospital for Special Surgery, New York
Angiocrine Bioscience

Active, not recruiting

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

Rotator Cuff Tears | Muscle Atrophy or Weakness | Safety Issues | Tendon Rupture - Shoulder

United States
GlaxoSmithKline
Q2 Solutions; York Bioanalytical Solution; BI Medical.Inc; SRL Mediserch.Inc; Parexel...

Completed

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

Asthma

Japan
Banc de Sang i Teixits
Complexo Hospitalario Universitario de A Coruña; Institut Guttmann; Academic...

Completed

Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury

Spinal Cord Injury Cervical

Spain
Texas Christian University

Active, not recruiting

Mapping Approaches to Prepare for Implementation Transfer (MAP-IT) (MAP-IT)

Mapping Approaches to Prepare for Implementation Transfer | Treatment Readiness and Induction Program

United States
Hiroshima University
KAWAMOTO FOODS CO., LTD.

Completed

Effect of Coadministration of Ume Paste (Prunus Mume) and Ginger Powder

Prediabetes

Japan
The First Affiliated Hospital of Soochow University
The Second People's Hospital of Huai'an; First Affiliated Hospital Bengbu Medical... and other collaborators

Recruiting

CAV Regimen for R/R AML

Acute Myeloid Leukemia

China
GlaxoSmithKline

Completed

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Romania, Russian Federation, Estonia, Peru, Poland, France, Chile, Hungary, Italy, Slovakia
C. R. Bard

Completed

Male External Catheters' Comparison of Comfort and Efficacy (MECCE)

Non-invasive Urine Output Management

United States
GlaxoSmithKline
Parexel

Completed

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Poland, United States, Russian Federation
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Mexico, Norway
University of Virginia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Neural-net Artificial Pancreas (NAP) (NAP)

Type1 Diabetes

United States
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline

Completed

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Puerto Rico, United States, Australia, Argentina, France, Germany, Japan, Netherlands, Russian Federation, Spain, Ukraine, Finland, Czechia, Poland, Belgium, Chile, Peru, South Africa, Sweden, Thailand, Israel, Korea, Republic of, C... and more
GlaxoSmithKline

Completed

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Poland, Romania, Russian Federation, Ukraine, Bulgaria, Estonia, Mexico, Korea, Republic of, Slovakia, Greece, China, Italy, Hungary, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, United States, Netherlands, Czechia
GlaxoSmithKline

Completed

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Czechia
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

Germany, Spain, United States, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Greece, Czechia

3

Subscribe